Treatment Rationale and Study Design for the PointBreak...

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Philip Bonomi, Mark A. Socinski, Ramaswamy Govindan, Shengyan Hong, Coleman Obasaju, Eduardo J. Pennella, Allicia C. Girvan, Susan C. Guba
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Year:
2009
Language:
english
DOI:
10.3816/clc.2009.n.035
File:
PDF, 100 KB
english, 2009
Conversion to is in progress
Conversion to is failed